Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
93.00    0.00 (0.00%)
Bid:
91.00
Ask:
95.00
Spread: 4.00 (4.396%)
Market Cap: £62.39m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Directorate change

7 Mar 2019 07:00

ECO Animal Health Group plc

7 March 2019

(AIM: EAH)

Directorate Change

ECO Animal Health Group plc announces that Peter Lawrence, having been with the Company since 1972 when he founded the business, will step down from his role as Non-Executive Chairman with effect from today. The Company also announces that Mr Richard Wood has been appointed to the Board as Non-Executive Chairman of the Company, also effective today. Peter and Richard will work closely together over the next few months to ensure an orderly handover of duties.

Richard Wood has considerable global animal health experience having built Genus plc from a small company privatised by the government, into a world leading animal genetics company. Richard currently sits on the board of Anpario plc as Senior Independent Director. Richard was previously a non-executive director of Avon Rubber plc and was also chairman of Ocean Harvest Technology Inc, a small manufacturer of therapeutic animal feeds using seaweeds.

Peter Lawrence commented:

“It has been my pleasure to work with the Company and its loyal employees and customers over the past 47 years. We are delighted that Richard has agreed to replace me as chairman, as he has vast industry knowledge and City experience which will allow him to lead the executive team during the Company’s next stage of growth.”

Marc Loomes (CEO) commented:

“On behalf of the Board I would like to sincerely thank Peter for his enormous contribution to the growth and development of the Company during his time with the business. We are delighted that Richard has agreed to take over the role of Chairman, as he brings significant sector and City experience to the Board. This experience will help support the expansion plans of ECO Animal Health, including investment in product development programmes and the broadening of our portfolio offer and new geographical presence.”

Richard Wood commented:

“I am delighted to succeed Peter Lawrence as Chairman. ECO Animal Health is an excellent business with a highly committed team. I have been impressed by the achievements of the management and I look forward to working with them to deliver the next stage of ECO Animal Health’s growth.”

In accordance with Schedule Two, paragraph (g) of the AIM Rules, Richard Kenneth Wood (aged 74) holds or has held in the past 5 years the following directorships and partnerships:

Current

Former directorships/partnerships within last five years

Anpario plc Atlantic Healthcare plc Avon Rubber P.L.C Innovis Limited Ocean Harvest Technology Inc. Silent Herdsman Holdings Limited

Save as disclosed above, there is no further information required to be disclosed in respect of Richard Wood pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

Contacts:

ECO Animal Health Group plc

Peter Lawrence

Marc Loomes

020 8336 6190

020 8447 6906

Spiro Financial

Anthony Spiro

IFC Advisory

Graham Herring

020 8336 6196

0203 934 6637

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

James White

Brough Ransom

020 7496 3000
Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005422/en/

Copyright Business Wire 2019

Date   Source Headline
4th Jun 20267:00 amRNSRenewal of revolving credit facility
14th Apr 20267:00 amRNSAppointment of Head of Business Development
31st Mar 20267:00 amRNSBoard Change
19th Mar 20267:00 amRNSFull Year Trading Update
11th Mar 20267:00 amRNSECOVAXXIN® MG favourable USDA safety assessment
11th Mar 20267:00 amRNSECOVAXXIN®?MG favourable USDA safety assessment
5th Mar 20264:19 pmRNSBlock Listing Return
26th Feb 20267:00 amRNSEU launch plans for ECOVAXXIN® MS
19th Jan 20261:50 pmRNSHolding(s) in Company
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
18th Dec 20257:00 amRNSExercise of Share Options by Director
9th Dec 20255:57 pmRNSHolding(s) in Company
4th Dec 20252:10 pmRNSDirector/PDMR Shareholding
1st Dec 20257:00 amRNSResults for the six months ended 30 September 2025
20th Nov 20259:47 amRNSReplacement: Notice of Results
20th Nov 20257:00 amRNSNotice of Results
10th Nov 20257:00 amRNSEMA Positive Opinion Received for ECOVAXXIN® MS
1st Oct 20257:00 amRNS-RHead of Global R&D
25th Sep 20253:15 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Trading Update and Notice of Interim Results
1st Sep 20257:00 amRNSAppointment of Joint Broker
29th Aug 20257:00 amRNSShare Awards to Executive Directors
28th Aug 20257:48 amRNSPosting of Annual Report and Notice of AGM
21st Aug 202512:29 pmRNSResult of General Meeting
13th Aug 20257:00 amRNSBlock Listing Return
6th Aug 20255:09 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSResults for the year ended 31 March 2025
8th Jul 20254:10 pmRNSNotice of General Meeting and Notice of Results
2nd May 20257:00 amRNSHolding(s) in Company
28th Apr 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSTrading Update
13th Mar 20257:00 amRNSR&D Day
3rd Mar 20257:00 amRNSSubmission of Marketing Authorisation Application
24th Feb 20254:08 pmRNSHolding(s) in Company
19th Feb 20257:00 amRNSDisposal of non-core assets
18th Feb 20257:00 amRNSBlock listing Interim Review
13th Feb 20257:00 amRNSNotice of R&D Day
31st Jan 20257:00 amRNSBoard Changes
20th Dec 20247:00 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSHolding(s) in Company
2nd Dec 202412:30 pmRNSShare Purchase by Executive Director
28th Nov 20247:00 amRNSResults for the Six Months Ended 30 September 2024
28th Oct 202412:57 pmRNSShare Awards to Executive Directors
22nd Oct 202411:00 amRNSEBT Share Purchase
21st Oct 20247:00 amRNSEBT Share Purchase
14th Oct 202411:07 amRNSEBT Share Purchase
9th Oct 20247:00 amRNSIssue of Equity and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.